Prognostic implications of chromosome 17p deletions in human medulloblastomas

Surinder K. Batra, Roger E. McLendon, Ja Seok Koo, Shobha Castelino-Prabhu, Herbert E. Fuchs, Jeffrey P. Krischer, Henry S. Friedman, Darell D. Bigner, Sandra H. Bigner

Research output: Contribution to journalArticlepeer-review

125 Scopus citations


DNA derived from medulloblastoma biopsies was analyzed to determine if deletions of the 17p region, mutations of the TP53 gene, or amplification of the c-myc, N-myc, EGFR (epidermal growth factor receptor), or MDM2 (murine double-minute-2) genes was indicative of a poor prognosis. Loss of heterozygosity for 17p, observed in 8/28 (29%) paired samples, was associated with a shortened survival period (p=0.045 by the logrank test). TP53 mutations occurred in 2/46 (4.3%) tumor samples. c-myc Amplification was seen in 3/43 (6.9%) cases, while none of the tumors contained amplified N-myc, EGFR, or MDM2 genes. These results demonstrate that, while only rare medulloblastomas contain TP53 gene mutations or amplification of the c-myc gene, loss of heterozygosity on chromosome 17p is indicative of a significantly worse prognosis among patients with these tumors. Further, these results provide a strong impetus for a prospective analysis of loss of heterozygosity in a cooperative group setting, which would include tumor staging, a selection of treatment modalities, and multivariate analyses.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalJournal of Neuro-Oncology
Issue number1
StatePublished - Feb 1995
Externally publishedYes


  • TP53
  • loss of heterozygosity
  • medulloblastomas
  • microsatellite
  • minisatellite
  • oncogenes
  • prognostic significance

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Prognostic implications of chromosome 17p deletions in human medulloblastomas'. Together they form a unique fingerprint.

Cite this